Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Artificial Intelligence in Drug Discovery Market to Hit USD 6.89 Billion by 2029…
Browse in-depth TOC on "Artificial Intelligence in Drug Discovery Market" Browse in-depth TOC on "Artificial Intelligence in Drug Discovery Market" 270 - Tables 50 - Figures 350 - Pages Based on therapeutic area,the artificial intelligence (AI) in drug discovery market is segmented into oncology, infectious diseases, neurology, metabolic diseases, cardiovascular diseases, immunology, mental health, and others (respiratory diseases, nephrology, dermatological diseases,...
PR Newswire
12/11/2024
Nasal Drug Delivery Technology Market Breakthrough in Patient Care, Projected…
Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=204829 Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=204829 202 – Pages 126 – Tables 37 – Figures Scope Of The Report Nasal Drug Delivery Technology Market Overview 1.Market Definition and Scope The Nasal Drug Delivery Technology Market encompasses a range of drug delivery systems that administer medications through the nasal cavity...
PR Newswire
12/11/2024
Survey: Unsustainable Regulatory Workloads Leave No Choice About AI Adoption
The study, conducted by Censuswide in September, is striking both in its confirmation of how vital AI-powered process change has become, and in its revelations about persistent barriers that are compromising companies' regulatory transformations. That is as soaring workloads overwhelm already-overstretched teams. The study, conducted by Censuswide in September, is striking both in its confirmation of how vital AI-powered process change has become, and in its revelations about persistent...
PR Newswire
12/11/2024
Hospital Sant Pau and Huawei join forces to accelerate digital transformation in…
Dr. Josep Munuera, Director of the Diagnostic Imaging Service at Sant Pau, discussed the potential of AI as a powerful tool to enhance and optimize processes such as imaging diagnostics and the development of predictive models. He emphasized that these advancements could enable a more efficient implementation of precision medicine, tailoring treatments to individual patient needs with greater accuracy and effectiveness. Dr. Josep Munuera, Director of the Diagnostic Imaging Service at Sant…
PR Newswire
12/11/2024
The Sigourney Award-2024 Recipients Honored For Outstanding Work Advancing…
"The 2024 recipients' work has uniquely and positively impacted populations, including the youngest among us, by expanding access and understanding of psychoanalysis as well as psychotherapy's benefits to professionals and the general public," says Dr. Deutsch. "The anonymous judges, who likewise conduct exemplary professional careers, evaluated work from 10 countries to select work that most closely aligned with Mary Sigourney's original intent." "The 2024 recipients'…
PR Newswire
12/11/2024
Kindeva Drug Delivery Appoints New CIO to Lead Digital Transformation Business…
"Staying ahead in a highly competitive market means taking advantage of the latest technologies. As CIO, Prakash will create a global IT roadmap enabling us to capitalize on the best-in-class technologies and future-proof our processes. His appointment marks a pivotal point in our growth strategy as we continue to innovate and invest in the right people and technologies to deliver business value." said Milton Boyer, CEO of Kindeva. "Staying ahead in a highly competitive market…
PR Newswire
12/11/2024
Exploring the $188 Billion Opportunity: Why AI is Set to Transform Global…
VANCOUVER, BC, Nov. 12, 2024 /PRNewswire/ -- Recently the World Economic Forum released a report that highlights AI's potential to relieve pressure on healthcare systems worldwide, with Mayo Clinic's early adoption showing how AI can drive progress. Elon Musk has also hinted that his company's Grok AI could have applications in medical image analysis. At this year's HLTH conference in Las Vegas, tech giants like Nvidia, Google, and Microsoft presented their latest AI healthcare tools. Meanwhile…
PR Newswire
12/11/2024
QuantalX Secures FDA Clearance for its breakthrough Delphi stimulator, advancing…
Delphi-MD was granted FDA Breakthrough Designation Device status twice, the first for the detection of patients at risk for stroke and dementia and the second for detection of NPH and prediction of treatment response to ventriculoperitoneal shunt (VPS) surgery. Delphi-MD was also selected for the prestigious FDA Total Product Life Cycle Advisory program (TAP), supporting the company's efforts to advance the successful adoption of the technology in the US healthcare market. Delphi-MD brain health…
PR Newswire
12/11/2024
Metabolon Services Used in Pioneering Multiomic Research on Brain Metabolism and…
Neurodegenerative diseases such as Alzheimer's and Parkinson's disease affect millions of people worldwide. Alzheimer's disease impacts an estimated 50 million people globally, and approximately 10 million new cases of dementia are diagnosed each year. The global cost of Alzheimer's and other dementias is estimated to be over $1 trillion annually, a number expected to double by 2030 as the world's population ages. Neurodegenerative diseases such as Alzheimer's and Parkinson's disease affect...
PR Newswire
12/11/2024
New Ipsos global survey shines a light on the myopia epidemic
Myopia, or short-sightedness, is predicted to impact half of the World's population and a staggering one billion people are predicted to have high myopia by 2050[2]. Myopia, or short-sightedness, is predicted to impact half of the World's population and a staggering one billion people are predicted to have high myopia by 2050 [2]. Higher degrees of myopia pose a greater risk of ocular complications that may lead to visual impairment or even blindness later in life. However, the earlier...
PR Newswire
12/11/2024
Gifthealth Announces Strategic Partnership with United Digestive
With over 25% of GIs on the platform, Gifthealth has established itself as the market-leading patient access solution in the gastroenterology space. The average practice using the Gifthealth platform experiences a provider productivity increase of 17-25% when fully engaged on the platform. With over 25% of GIs on the platform, Gifthealth has established itself as the market-leading patient access solution in the gastroenterology space. The average practice using the Gifthealth platform...
PR Newswire
12/11/2024
Invitation to Immunovia's Q3 presentation
Telephone numbers and webcastCall any of the numbers below to participate via telephone. Please dial in a few minutes before the presentation starts. Telephone numbers and webcastCall any of the numbers below to participate via telephone. Please dial in a few minutes before the presentation starts. Sweden : +46 (0)8 5051 0031United Kingdom : +44 (0) 207 107 06 13United States : +1 (1) 631 570 56 13 Link to the webcast:...
PR Newswire
12/11/2024
Theriva™ Biologics Reports Third Quarter 2024 Operational Highlights and…
Target patient enrollment of 92 evaluable patients achieved in the VIRAGE Phase 2b clinical trial of VCN-01 in patients with metastatic pancreatic ductal adenocarcinomaManufacturing funding awarded by the Spanish Government's National Knowledge Transfer ProgramData and Safety Monitoring Committee Review of Phase 1b/2a SYN-004 in allogeneic hematopoietic cell transplant recipients recommends expansion to Cohort 3Orphan Medicinal Product Designation granted by the European...
Nasdaq GlobeNewswire
12/11/2024
Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine…
New preclinical data demonstrates that CMV antigens identified with Evaxion's AI-Immunology™ platform trigger targeted immune responses Results also showcase the successful design of a proprietary prefusion glycoprotein B (gB) antigen with ability to neutralize the virusEvaxion is advancing these new findings to develop a multi-component CMV vaccine candidateAbout 1 in 200 babies is born with congenital CMV infection and the virus infects approximately 60% to 70% of adults in...
Nasdaq GlobeNewswire
12/11/2024
OrganOx and eGenesis Announce Exclusive Clinical Co-Development Agreement for…
Partnership aims to advance a novel liver support system integrating a leading organ preservation platform with whole biologic livers to address a major unmet need The companies will focus on the estimated 35,000 patients in the United States hospitalized each year for acute or acute-on-chronic liver failure1,2 . The efficacy of existing liver support options is limited, and patients in liver failure face mortality rates as high as 50 percent 2. For some patients, utilizing a human...
Nasdaq GlobeNewswire
12/11/2024
Ramsay Generale de Sante: preparatory documents availability for the 2024…
PRESS RELEASE Paris, 12 thNovember 2024COMBINED GENERAL MEETING OF DECEMBER 12, 2024 Arrangements for making available or consulting the preparatory documents for the Ramsay Générale de Santé General Meeting of December 12, 2024 The shareholders of Ramsay Générale de Santé are invited to participate in the Combined General Meeting on Thursday, December 12, 2024, which will take place at 10 a.m. at the Apostrophe 83 avenue Marceau 75116 Paris.The meeting notice...
Nasdaq GlobeNewswire
12/11/2024
SciBase announces collaboration for prediction of atopic dermatitis in infants
Inge Kortekaas Krohn, assistant professor SKIN Research Group comments: Inge Kortekaas Krohn, assistant professor SKIN Research Group comments: ''Early detection of a child that is at risk of developing atopic dermatitis and subsequent adequate preventive measures can reduce disease burden and further progression to other atopic diseases like food allergy, allergic asthma or allergic rhinitis. Therefore, the present collaboration holds the potential to improve prediction, prevention and...
PR Newswire
12/11/2024
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024…
Announced additional interim data from ongoing Phase 1 clinical study of ORX750, a novel orexin receptor 2 (OX2R) agonist, in acutely sleep-deprived healthy volunteers that further support best-in-class potential of ORX750 in narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH); Presentation of Phase 1 data planned for medical congress in Q2 2025Initiated Phase 2a clinical study of ORX750 in patients with NT1, NT2 and IH; Phase 2a data across all three...
Nasdaq GlobeNewswire
12/11/2024
Nevro's HFX iQ™ Spinal Cord Stimulation with AI Technology Receives CE Mark…
HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief.* HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief.* "We are thrilled to…
PR Newswire
12/11/2024
iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates
- EMA granted clearance to advancebelrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in the EU - Interim data from inupadenant Phase 2 A2A-005 in 2L NSCLC at ESMO-IO - Completed enrollment of EOS-984 Phase 1 monotherapy dose escalation and initiated dosing of EOS-984 + pembrolizumab combination - Pro forma cash and investment balance of $683.9 million as of September 30, 2024 expected to provide runway through 2027 across a number...
Nasdaq GlobeNewswire
12/11/2024
Novo Holdings co-leads $181.4 million Series D financing in Alentis Therapeutics…
The oversubscribed Series D round was led by OrbiMed, with Novo Holdings and Jeito Capital acting as co-leads. The financing round included new participation from Frazier Life Sciences, Longitude Capital, Catalio Capital, Piper Heartland Healthcare Capital, and Avego Bioscience Capital, along with continued support from existing backers including notably RA Capital Management, Morningside Venture Investments, BB Pureos and BPI France through its InnoBio 2 fund. The oversubscribed Series D…
PR Newswire
12/11/2024
Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational…
Cash position of $19.6 million as of September 30, 2024 Cash position of $19.6 million as ofSeptember 30, 2024 Management hosting conference call and webcast today at 8:30 a.m. ET SAN DIEGOandCALGARY, AB , Nov. 12, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced third quarter financial results and operational highlights. Wayne Pisano, Chair...
PR Newswire
12/11/2024
Coloplast A/S - Notice of Annual General Meeting 2024
The Annual General Meeting of Coloplast A/S will be held onThursday, 5 December 2024 at 3:30 pm CETat the premises of Coloplast A/S, Holtedam 3 in Humlebæk (the Aage Louis-Hansen Auditorium), Humlebæk, Denmark. The notice of the Annual General Meeting is enclosed. For further information, please contactInvestors and analystsAnders Lonning-SkovgaardExecutive Vice President, CFOTel. +45 4911 1111Aleksandra DimovskaVice President, Investor RelationsTel. +45 4911 1800 / +45...
Nasdaq GlobeNewswire
12/11/2024
Gan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1…
The Phase 1 clinical trial (CTR20240663) was a randomized, open-label, first-in-human study involving 92 participants, designed to assess the bioavailability, pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of GZR18 tablets in healthy adult participants. The study also evaluated the effect of meal timing on the drug's PK, PD, safety, and tolerability. The Phase 1 clinical trial (CTR20240663) was a randomized, open-label, first-in-human study involving 92 participants,...
PR Newswire
12/11/2024
Altri Comunicati
